<DOC>
	<DOCNO>NCT00259779</DOCNO>
	<brief_summary>To assess Symbicort forte Turbuhaler ( two week ) effective oral course prednisolone + Oxis Turbuhaler ( two week ) treatment acute exacerbation Chronic Obstructive Pulmonary Disease ( COPD ) .</brief_summary>
	<brief_title>Comparison Between Symbicort® Prednisolone COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Patients chronic obstructive pulmonary disease acute exacerbation After acute treatment simple pulmonary function test show value 30 % 60 % predict normal value . Patients , , base clinical examination initial acute treatment , candidate course oral steroid treatment acute symptom due chronic obstructive pulmonary disease Diagnosis/history asthma Oxygen uptake ( saturation ) &lt; 92 % initial acute treatment A requirement regular use oxygen therapy Regular treatment inhale steroid &gt; 1 000 µg/day study entry Additional inclusion exclusion criterion evaluate investigator</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>COPD</keyword>
</DOC>